Literature DB >> 6204793

Serum alpha fetoprotein heterogeneity as a means of differentiating between primary hepatocellular carcinoma and hepatic secondaries.

P K Buamah, I Gibb, G Bates, A M Ward.   

Abstract

The concanavalin A binding characteristics of serum alpha-fetoprotein (AFP) were investigated in patients with primary hepatocellular carcinoma and hepatic secondaries using affinity column chromatography and radioimmunoassay. The primary hepatocellular carcinoma (n = 21) was associated with a median concanavalin A non-reactive AFP fraction of 7.4% (range 1.6 - 18.8) while the hepatic secondaries (n = 8) had a median concanavalin A non-reactive AFP fraction of 50.7% (range 26.6 - 91.7). A simple diagnostic test for differentiating between the two groups of patients is proposed.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6204793     DOI： 10.1016/0009-8981(84)90277-8

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN： 0009-8981            Impact factor:   3.786


  9 in total

1.  Serial serum AFP heterogeneity changes in patients with hepatocellular carcinoma during chemotherapy.

Authors:  P K Buamah; C Cornell; O F James; A W Skillen; A L Harris
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

2.  Alterations of glycan branching and differential expression of sialic acid on alpha fetoprotein among hepatitis patients.

Authors:  Gautam Mondal; Urmimala Chatterjee; Yogesh K Chawla; Bishnu Pada Chatterjee
Journal:  Glycoconj J       Date:  2010-12-14       Impact factor: 2.916

3.  Development of glycoprotein capture-based label-free method for the high-throughput screening of differential glycoproteins in hepatocellular carcinoma.

Authors:  Rui Chen; Yexiong Tan; Min Wang; Fangjun Wang; Zhenzhen Yao; Liwei Dong; Mingliang Ye; Hongyang Wang; Hanfa Zou
Journal:  Mol Cell Proteomics       Date:  2011-04-07       Impact factor: 5.911

4.  Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans.

Authors:  Timothy M Block; Mary Ann Comunale; Melissa Lowman; Laura F Steel; Patrick R Romano; Claus Fimmel; Bud C Tennant; W Thomas London; Alison A Evans; Baruch S Blumberg; Raymond A Dwek; Tajinder S Mattu; Anand S Mehta
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-10       Impact factor: 11.205

5.  Identification and development of fucosylated glycoproteins as biomarkers of primary hepatocellular carcinoma.

Authors:  Mary Ann Comunale; Mengjun Wang; Julie Hafner; Jonathan Krakover; Lucy Rodemich; Brent Kopenhaver; Ronald E Long; Omer Junaidi; Adrian M Di Bisceglie; Timothy M Block; Anand S Mehta
Journal:  J Proteome Res       Date:  2009-02       Impact factor: 4.466

6.  Tumour markers: An overview.

Authors:  T Malati
Journal:  Indian J Clin Biochem       Date:  2007-09

7.  Surrogate markers of efficacy for medical treatment of viral hepatitis.

Authors:  Timothy M Block; W Thomas London
Journal:  Biotechnol Healthc       Date:  2004-10

8.  Serum profile of low molecular weight fucosylated glycoproteins for early diagnosis of hepatocellular carcinoma.

Authors:  Weirong Yao; Kaiyu Wang; Yu Jiang; Zhufeng Huang; Yiyun Huang; Huihui Yan; Suhong Huang; Min Chen; Jian Liao
Journal:  Oncol Lett       Date:  2020-06-11       Impact factor: 2.967

9.  Unique and differential protein signatures within the mononuclear cells of HIV-1 and HCV mono-infected and co-infected patients.

Authors:  Nawal M Boukli; Vivekananda Shetty; Luis Cubano; Martha Ricaurte; Jordana Coelho-Dos-Reis; Zacharie Nickens; Punit Shah; Andrew H Talal; Ramila Philip; Pooja Jain
Journal:  Clin Proteomics       Date:  2012-09-07       Impact factor: 3.988
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.